Table 2.

Most noteworthy differences between CAR-T based treatments and CAR-NK based treatments.

CD19 CAR-T	CD19 CAR-NK
>400 clinical trials	13 clinical trials
3 commercial products [40]	0 commercial products
Autologous treatment [81]	Allogenic treatment [83]
Poor expansion directly correlated with patient relapse [80]	Short lifespan [78]
Less resistant to genetic engineering	More resistant to genetic engineering
(Up to 80% transduced cells) [81]	(40–60% transduced cells) [82,83]
Activated through CD3ζ 4-1BB and CD28 [88]	Activated through CD3ζ, 4-1BB, DAP10, DAP12, and FcRγ [89,90]